288 related articles for article (PubMed ID: 19428228)
1. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment.
Giaccari A; Sorice G; Muscogiuri G
Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):365-77. PubMed ID: 19428228
[TBL] [Abstract][Full Text] [Related]
2. Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.
Spallarossa P; Barsotti A; Cordera R; Ghigliotti G; Maggi D; Brunelli C
J Endocrinol Invest; 2004 May; 27(5):485-95. PubMed ID: 15279085
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
4. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
5. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.
Akalin S; Berntorp K; Ceriello A; Das AK; Kilpatrick ES; Koblik T; Munichoodappa CS; Pan CY; Rosenthall W; Shestakova M; Wolnik B; Woo V; Yang WY; Yilmaz MT;
Int J Clin Pract; 2009 Oct; 63(10):1421-5. PubMed ID: 19769698
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of diabetes in metabolic syndrome].
Pelikánova T
Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
[TBL] [Abstract][Full Text] [Related]
7. From hyperglycemia to the risk of cardiovascular disease.
Leiter LA
Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
[TBL] [Abstract][Full Text] [Related]
8. Metabolic memory: Evolving concepts.
Misra A; Bloomgarden Z
J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
[TBL] [Abstract][Full Text] [Related]
9. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
[TBL] [Abstract][Full Text] [Related]
10. Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?
van Raalte DH; Verchere CB
Diabetes Obes Metab; 2017 Sep; 19(9):1205-1213. PubMed ID: 28295962
[TBL] [Abstract][Full Text] [Related]
11. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update.
Ceriello A; Davidson J; Hanefeld M; Leiter L; Monnier L; Owens D; Tajima N; Tuomilehto J;
Nutr Metab Cardiovasc Dis; 2006 Oct; 16(7):453-6. PubMed ID: 16934443
[TBL] [Abstract][Full Text] [Related]
12. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A
Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989
[TBL] [Abstract][Full Text] [Related]
13. Acute and chronic effects of hyperglycaemia on glucose metabolism: implications for the development of new therapies.
Yki-Järvinen H
Diabet Med; 1997 Aug; 14 Suppl 3():S32-7. PubMed ID: 9272611
[TBL] [Abstract][Full Text] [Related]
14. Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus.
Galligan A; Greenaway TM
Intern Med J; 2016 May; 46(5):540-9. PubMed ID: 27170238
[TBL] [Abstract][Full Text] [Related]
15. The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes.
Yu PC; Bosnyak Z; Ceriello A
Diabetes Res Clin Pract; 2010 Jul; 89(1):1-9. PubMed ID: 20494468
[TBL] [Abstract][Full Text] [Related]
16. [Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].
Ampudia-Blasco FJ; Ceriello A
Med Clin (Barc); 2010 Sep; 135 Suppl 2():33-9. PubMed ID: 21420536
[TBL] [Abstract][Full Text] [Related]
17. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
18. Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment.
Aroda VR; Eckel RH
Diabetes Obes Metab; 2022 Dec; 24(12):2297-2308. PubMed ID: 35929480
[TBL] [Abstract][Full Text] [Related]
19. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
Zoungas S; Arima H; Gerstein HC; Holman RR; Woodward M; Reaven P; Hayward RA; Craven T; Coleman RL; Chalmers J;
Lancet Diabetes Endocrinol; 2017 Jun; 5(6):431-437. PubMed ID: 28365411
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk and glycemic control.
Cheng AY; Leiter LA
CMAJ; 2009 Apr; 180(9):907-8. PubMed ID: 19398731
[No Abstract] [Full Text] [Related]
[Next] [New Search]
